附桂管食通颗粒提高晚期食管癌生存率临床研究  

Clinical Study on Fugui Guanshitong Granules Improving Survival Rates of Patients with Advanced Esophageal Cancer

作　　者：郑玉玲[1] 陈建设[2] 马纯政[2] 许彦超 陈晓琦[3] 林建州 李军赛 贺文龙 仝新朵 秦善文[3] 张丽菡 ZHENG Yuling;CHEN Jianshe;MA Chunzheng;XU Yanchao;CHEN Xiaoqi;LIN Jianzhou;LI Junsai;HE Wenlong;TONG Xinduo;QIN Shanwen;ZHANG Lihan(He'nan University of Chinese Medicine,Zhengzhou He'nan 450046,China;He'nan Province Hospital of Traditional Chinese Medicine,Zhengzhou He'nan 450003,China;The First Affiliated Hospital of He'nan University of Chinese Medicine,Zhengzhou He'nan 450003,China;Linzhou Hospital of Traditional Chinese Medicine,Linzhou He'nan 456500,China;Jia County of Chinese Medicine,Jiaxian He'nan 467100,China;Zhang Zhongjing Hospital in Nanyang,Nanyang He'nan 473000,China;Third Affiliated Hospital of He'nan University of Traditional Chinese Medicine,Zhengzhou He'nan 450003,China;He'nan Cancer Hospital,Zhengzhou He'nan 450003,China)

机构地区：[1]河南中医药大学,河南郑州450046 [2]河南省中医院,河南郑州450003 [3]河南中医药大学第一附属医院,河南郑州450003 [4]林州市中医院,河南林州456500 [5]郏县中医院,河南郏县467100 [6]南阳张仲景医院,河南南阳473000 [7]河南中医药大学第三附属医院,河南郑州450003 [8]河南省肿瘤医院,河南郑州450003

出　　处：《新中医》2023年第18期124-130,共7页New Chinese Medicine

基　　金：国家中医药百千万人才支持计划-岐黄学者(国中医药人教涵[2018]284号);全国名老中医药专家传承工作室建设项目(国中医药人教函[2022]75号);国家中医临床研究基地科研专项(2019JDZX001,2019JDZX028)。

摘　　要：目的:研究附桂管食通颗粒对脾肾阳虚、顽痰痼血型晚期食管癌患者治疗后42 d生存率、T细胞亚群、食管癌相关肿瘤标志物的影响。方法:纳入9个中心共120例患者,利用区组随机法分为试验1组、试验2组、对照组各40例。试验1组给予附桂管食通颗粒合丁香管食通含化丸;试验2组给予丁香管食通含化丸;对照组给予当归补血汤合桂枝人参汤颗粒,疗程为42 d。比较3组治疗42 d后的生存率、T细胞亚群(CD3^(+)、CD4^(+)、CD8^(+))及癌胚抗原(CEA)、鳞状上皮细胞癌抗原(SCCA),并进行安全性评价。结果:试验1组生存率88.6%、试验2组生存率86.8%、对照组生存率72.2%,3组比较,差异无统计学意义(P>0.05)。治疗后,3组CD4^(+)、CD8^(+)、CEA在时间上差异均有统计学意义(P<0.05),组间差异无统计学意义(P>0.05)。3组CD3^(+)、SCCA在组间和时间上差异均无统计学意义(P>0.05)。结论:附桂管食通颗粒可一定程度提高晚期食管癌患者生存率,并提高机体免疫功能。Objective:To study the effect of Fugui Guanshitong Granules on survival rates,T lymphocytes and tumor markers related to esophageal cancer in patients with advanced esophageal cancer of spleen-kidney yang deficiency and lingering phlegm and obstinate blood type in 42 days after treatment.Methods:A total of 120 cases of patients from nine centers were included and divided into the trial group1,the trial group 2 and the control group according to the block randomization method,with 40 cases in each group.The trial group 1 was treated with Fugui Guanshitong Granules and Dingxiang Guanshitong Hanhua Pills;the trial group 2 was treated with Dingxiang Guanshitong Hanhua Pills;the control group was treated with Danggui Buxue Decoction and Guizhi Renshen Decoction Granules.All the groups were treated for 42 days.The survival rates,T lymphocytes(CD3^(+) ,CD4^(+) ,CD8^(+) ),carcinoembryonic antigen(CEA),and squamous cell carcinoma antigen(SCCA) in the three groups were compared after 42 days of treatment,and the safety was evaluated.Results:The survival rate was 88.6% in the trial group 1,86.8%in the trial group 2,and 72.2% in the control group,there was no significant difference among the three goups(P>0.05).After treatment,the differences of CD4^(+) ,CD8^(+) ,and CEA in the three groups were significant in time(P<0.05),but there was no significant difference in the comparison among the three groups(P<0.05).There was no significant difference in CD3^(+) and SCCA among the three groups or the comparison of time(P>0.05).Conclusion:Fugui Guanshitong Granules for patients with advanced esophageal cancer can improve their survival rates and immune function.

关 键 词：晚期食管癌 脾肾阳虚 顽痰痼血证 附桂管食通 生存率 T淋巴细胞 

分 类 号：R735.1[医药卫生—肿瘤]